me 6

VT-ME6 is a potent and selective sphingosine kinase 2 inhibitor. VT-ME6, contained a quaternary ammonium group as a warhead and established that a positively charged moiety is necessary for engaging key amino acid residues in the enzyme binding pocket.13,14 This compound is moderately potent (Ki = 8 lM) and displays three-fold selectivity for SphK2 over SphK1. Sphingosine-1-phosphate (S1P) is a ubiquitous, endogenous small molecule that is synthesized by two isoforms of sphingosine kinase (SphK1 and 2). Intervention of the S1P signaling pathway has attracted significant attention because alteration of S1P levels is linked to several disease states including cancer, fibrosis, and sickle cell disease.

Me6TREN 4HCl is a potent and efficacious mobilizing agent of hematopoietic stem and progenitor cells (HSPCs) that can act by activating MMP-9 expression and disrupting the SDF-1α/CXCR4 axis, exhibiting more significant mobilizing effects than G-CSF or AMD

6-Aminocaproic acid-(S,R,S)-AHPC-Me serves as a ligand and linker for the E3 ubiquitin ligase in PROTACs, facilitating the synthesis of PVD-06 for research in oncology.

5'-O-DMT-N6-Me-2'-dA is a nucleoside that exhibits protective and modification effects.

6-Me-ATP (N6-Methyl-ATP), a N6-modified adenosine triphosphate (ATP) derivative, exhibits strong binding affinity for glycogen synthase kinase 3 (GSK3) and serves as the phosphate donor in GSK3β-catalyzed phosphorylation of its substrate peptide [1].

6-Me-ATP (N6-Methyl-ATP) trisodium, an N6-modified ATP derivative, exhibits high binding affinity for GSK3 and effectively serves as the phosphate group donor in GSK3β-catalyzed phosphorylation of its substrate peptide [1].

N-Me-Thalidomide-NH-C6-NH2 is an E3 ubiquitin ligase ligand-linker conjugate (E3 Ligase Ligand-linker conjugate). It can be utilized in the synthesis of Anti-inflammatory agent 70.

Mal-N(Me)-C6-N(Me)-PNU-159682 (Compound 27) is an active molecular conjugate used in antibody-drug conjugates (ADCs), consisting of the ADC linker Mal-N(Me)-C6-N(Me) and the potent cytotoxin PNU-159682. This compound selectively delivers its payload to cells expressing CD46 and releases PNU-159682 through cathepsin B cleavage of the linker, inducing DNA damage and apoptosis. Mal-N(Me)-C6-N(Me)-PNU-159682 has demonstrated sustained tumor regression in patient-derived xenograft (PDX) models of non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).

Acyclovir mixture with hydrocortisone is used for Herpes simplex labialis.

1. Methyl eugenol (4-allylveratrole) is a natural constituent of the essential oils of a number of plants widely used in foodstuffs as flavouring agents, in view of the carcinogenic potential of ME, the need to check its presence in food products with effective analytical methods. 2. Methyleugenol has insecticidal properties. 3. Methyleugenol can inhibit the production of nitric oxide and decreased the protein expression of inducible nitric oxide synthase, it down-regulates the production of pro-inflammatory cytokines in the ischemic brain as well as in immunostimulated mixed glial cells; indicates that methyleugenol could be useful for the treatment of ischemia/inflammation-related diseases. 4. Methyleugenol has cytotoxicity and genotoxicity. 5. Intravenous (i.v.) treatment with methyleugenol (ME) in either anesthetized or conscious rats elicits hypotension, an effect that seems related to an active vascular relaxation rather than withdrawal of sympathetic tone. 6. Methyleugenol has antinociceptive effect on the second phase of formalin-induced pain, may be due to the inhibition of N-methyl-d-aspartic acid (NMDA) receptor-mediated hyperalgesia via GABA(A) receptors. 7. Methyleugenol has elaxant and antispasmodic actions on guinea-pig isolated ileum.

(S,R,S)-AHPC-Me dihydrochloride, also known as VHL ligand 2 dihydrochloride, is a chemical compound used in the synthesis of ARV-771. ARV-771 is a BET PROTAC degrader that relies on von Hippel-Landau (VHL) E3 ligase and exhibits potent degradation of BET proteins in castration-resistant prostate cancer (CRPC) cells, with a DC50 of less than 1 nM. This compound acts as the VHL ligand, specifically the (S,R,S)-AHPC-based VHL ligand, facilitating the recruitment of von Hippel-Lindau (VHL) protein.

Nε,Nε,Nε-Trimethyllysine chloride (Lys(Me)3-OH Chloride) is a methylated derivative of lysine, found in histone proteins and serves as a coenzyme in fatty acid oxidation. It is a precursor for carnitine, generated by S-adenosyl-L-methionine on lysine residues. Upon proteolysis, it is converted to 3-hydroxy-6-N-trimethyllysine by mitochondrial 6-N-trimethyllysine dioxygenase, initiating carnitine biosynthesis.

Fmoc-Phe-Thr(psi(Me,Me)pro)-OH is an essential organic compound for life sciences research, catalog number T64451, CAS number 1196703-48-6.

Boc-N-Me-Leu-OH, with catalog number T65045 and CAS number 53363-89-6, is a valuable organic compound for life sciences research.

Fmoc-D-N-Me-Val-OH, catalog number T65652 and CAS number 103478-58-6, is a valuable organic compound for life sciences research.

Fmoc-N-Me-Glu(OtBu)-OH is a valuable organic compound for life sciences research (catalog number: T65703; CAS number: 200616-40-6).

Boc-N-Me-Tyr(Bzl)-OH is a valuable organic compound for life sciences research [Catalog No.: T66116, CAS No.: 64263-81-6].

Boc-N-Me-Ala-OH is a useful organic compound for research related to life sciences. The catalog number is T67523 and the CAS number is 16948-16-6.

AI-10-47 (1H-Benzimidazole, 2-(2-pyridinyl)-6-(trifluoromethoxy)-AI-10-47) is a small molecule inhibitor of CBFβ-RUNX binding(IC50 : 3.2 μM).

Methyl eugenol (Standard) is a reference standard for research and analysis in studies involving Methyl eugenol. 1. Methyl eugenol (4-allylveratrole) is a natural constituent of the essential oils of a number of plants widely used in foodstuffs as flavouring agents, in view of the carcinogenic potential of ME, the need to check its presence in food products with effective analytical methods. 2. Methyleugenol has insecticidal properties. 3. Methyleugenol can inhibit the production of nitric oxide and decreased the protein expression of inducible nitric oxide synthase, it down-regulates the production of pro-inflammatory cytokines in the ischemic brain as well as in immunostimulated mixed glial cells; indicates that methyleugenol could be useful for the treatment of ischemia/inflammation-related diseases. 4. Methyleugenol has cytotoxicity and genotoxicity. 5. Intravenous (i.v.) treatment with methyleugenol (ME) in either anesthetized or conscious rats elicits hypotension, an effect that seems related to an active vascular relaxation rather than withdrawal of sympathetic tone. 6. Methyleugenol has antinociceptive effect on the second phase of formalin-induced pain, may be due to the inhibition of N-methyl-d-aspartic acid (NMDA) receptor-mediated hyperalgesia via GABA(A) receptors. 7. Methyleugenol has elaxant and antispasmodic actions on guinea-pig isolated ileum.